BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 927 filers reported holding BAXTER INTL INC in Q4 2016. The put-call ratio across all filers is 0.70 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $8,000 | -98.9% | 90 | -99.0% | 0.01% | -99.1% |
| Q4 2020 | $697,000 | -0.1% | 8,685 | 0.0% | 0.56% | -7.6% |
| Q3 2020 | $698,000 | -9.8% | 8,685 | -3.3% | 0.60% | -8.1% |
| Q2 2020 | $774,000 | -12.5% | 8,985 | -17.6% | 0.66% | -25.0% |
| Q1 2020 | $885,000 | -3.0% | 10,905 | 0.0% | 0.87% | +21.4% |
| Q4 2019 | $912,000 | -8.2% | 10,905 | -4.0% | 0.72% | -10.1% |
| Q3 2019 | $993,000 | +14.0% | 11,355 | +6.8% | 0.80% | +5.1% |
| Q2 2019 | $871,000 | +0.8% | 10,630 | 0.0% | 0.76% | +0.8% |
| Q1 2019 | $864,000 | +26.5% | 10,630 | +2.4% | 0.76% | +10.5% |
| Q4 2018 | $683,000 | -18.4% | 10,380 | -4.4% | 0.68% | -5.4% |
| Q3 2018 | $837,000 | +1.6% | 10,855 | -2.7% | 0.72% | -1.6% |
| Q2 2018 | $824,000 | -99.9% | 11,155 | -8.2% | 0.73% | +2.5% |
| Q1 2018 | $790,561,000 | -1.2% | 12,155 | -1.9% | 0.72% | +8.0% |
| Q4 2017 | $800,566,000 | +4.0% | 12,385 | +0.9% | 0.66% | +0.3% |
| Q3 2017 | $770,068,000 | +6.2% | 12,272 | +2.5% | 0.66% | +5.6% |
| Q2 2017 | $724,785,000 | +12.5% | 11,972 | -3.6% | 0.63% | +9.2% |
| Q1 2017 | $644,205,000 | +984.5% | 12,422 | -7.3% | 0.57% | +941.8% |
| Q4 2016 | $59,402,000 | – | 13,397 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
| Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
| Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
| TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
| GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
| Third Point | 4,000,000 | $344,400,000 | 4.72% |
| Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
| Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
| Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
| Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |